A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation;Ocena przydatności reakcji immunohistochemicznych w róznicowaniu miȩdzybtoniaka ztosliwego optucnej z rakami niedrobnokomorkowymi naciekajqcymi opiucnq i odczynowym rozrostem miȩdzybłonka

Pneumonologia i Alergologia Polska

Volumn 75, Issue 1, 2007, Pages 57-69

  Szczepulska Wójcik, Ewa ^a   Langfort, Renata ^a   Roszkowski Śliz, Kazimierz ^b  

^a INSTYTUT GRU LICY I CHORÓB P UC   (Poland)

^b Immun Inst Gruzlicy i Chorob Pluc   (Poland)

Author keywords

Immunohistochemical stains; Malignant mesothelioma; Mesothelial proliferation; Non small cell carcinoma; Pleura

Indexed keywords

EID: 34347359605     PISSN: 08677077     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Astoul P. Malignant mesothelioma, W: Light R., Lee G. Textbook of Pleural Diseases. Arnold Publishers, London 2003; 435-444.
2. Szczepulska-Wójcik E., Langfort R. Miȩdzyblonlak złośliwy oplucnej - klasyfikacja histopatologiczna, stopień zaawansowania i dlagnostyka mikroskopowa. Pneumonol. Alegol. Pol. 2005; 73: 285-291.
3. Saldi A., Santini D., Vasaturo F. i wsp. Prognostic significance of cyclooxygenase-2 (COX-2) and expression of cell cycle inhibitors p21 and p27 in human pleural malignant mesothelioma. Thorax 2004; 59; 428-433.
4. Fljołek J., Wiatr E., Langfort R. i wsp. Nawracaja̧ce odmy opiucnowe jako jedyna manifestacja miȩdzybloniaka opłucnej. Pneumonol. Alergol. Pol. 2005; 73; 381-386.
5. Attanos R.L., Webb R., Dojcinov S.D., Gibbs A.R. Malignant epithelioid mesothelioma: anti-mesothelial marker expression with histological pattern. Histopathol. 2001; 39; 584-588.
6. Travis W., Brambilla E., Müller-Hermelink H., Harris C. Pathology and genetics of tumours of lung, pleura, thymus and heart. World Health Organization Classification of Tumours. Lyon 2004;125-144.
7. Attanos R.L., Griffin A., Gibbs A.R. The use of immunohistochemistry in distinguishing reactive from neoplastlc mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2. Histopathol. 2003, 43; 231-238.
8. Cagle P.T., Churg A. Differentual diagnosis of benign and malignant mesothellal proliferations on pleural biopsies. Arch. Pathol. Lab. Med. 2005; 129; 1421-1427.
9. Churg A., Colby T., Cagle P. i wsp. The separation of benign and malignant mesothelial proliferations. Am. J. Surg. Pathol. 2000; 24; 1183-1200.
10. Ordonez N. Immunohistochemical diagnosis of epithelioid mesotheliomas: a critical review of old markers, new markers. Hum. Pathol. 2002; 33; 953-967.
11. Riera J., Astengo-Osuna C., Longmate J. i wsp. The immunohistochemical diagnostic panel for epithelial mesothelioma. Am. J. Surg. Pathol. 1997; 21; 1409-1419.
12. Abutaily A., Addis B., Roche W. Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma; a critical evaluation of new antibodies. J. Clin. Pathol. 2002; 55; 662-868.
13. Brockstedt U., Gulyas M., Dobra K. i wsp. An optimised battery of eight antibodies that can distinguish most cases of epithelial mesothelioma from adenocarcinoma. Am. J. Clin. Pathol. 2000; 114; 203-209.
14. Clover J. Oates J. Edwards C. Anti-cytokeratin 5/6: A positive marker for epithelioid mesothelioma. Histopathology 1997; 31; 140-143.
15. Curry P,, Buther D., Fisher C. i wsp. Value of the mesothelium-associated antibodies Thrombomodulin, Cytokeratln 5/6, Calretynin, and CD44 In distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura. Mod. Pathol. 2000; 13; 107-12.
16. Doglioni C., Dei Tos A. Laurino L. i wsp. Calietinin: a novel immunocytochemical marker for mesothelioma. Am. J. Surg. Pathol. 1996; 20: 1037-1046.
17. Garcia-Prats M.D., Ballestin C., Sotelo T., Lopez-Encuentra A., Myordomo J.I. A comparitive evaluation of immunohistochemical markers for differential diagnosis of malignant pleural tumors. Histopathology 1998; 462-472.
18. Gonzalez-Lois C., Ballestin C., Sotelo M.T., Lopez-Rios F., Garcia-Prats M.D., Villena V. Combined ise of novel epithelial (MOC-31) and mesothelial (HBME-1) immunohistochemical markers for optimal first line diagnostic distinction between mesothelioma and metastatic carcinoma in pleura. Histopathology 2001; 38: 528-534.
19. Gotzos V., Vogt P., Cello M. The calcium binding protein calretinin is a selective marker for malignant pleural mesotheliomas of epithelial type. Path. Res. Pract. 1996; 192; 137-147.
20. Nakamura N., Miyagi E., Murata S. i wsp. Expression of Thyroid Transcription Factor-1 in normal and neoplastlc lung tissues. Mod. Pathol. 2002; 15; 1058-1067.
21. Ordonez N, Value of Thyroid Transcription Factor-1, E-cadherin, BG8, WT1, and CD44S Immunostanlng in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma. Am. J. Surg. Pathol. 2000; 24; 598-606.
22. Ordonez N.G. Immunohistochemical diagnosis of epithelioid mesothelioma. An update. Arch. Pathol. Lab. Med. 2005; 129; 1407-1414.
23. Wick M., Moran C., Millis S. i wsp. Immunohistochemical differential diagnosis of pleural effusions, with emphasis on malignant mesothelioma. Cur, Opin. Pulm. Med, 2001; 7; 187-192.
24. Ordonez N. The immunohistochemlcal diagnosis of mesothelioma. Am. J. Surg. Pathol. 2003; 27; 1031-1051.
25. Tang P., Vatsia S., Teichberg S. i wsp, Pulmonary adenocarcinoma simulating malignant mesothelioma. Arch. Pathol. Lab, Med. 2001; 125; 1598-1600.
26. Wick M. Pleural cytology, tumor markers and immunohistochemistry. W: Light R., Lee Y. Textbook of Pleural Diseases. Arnold Publishers, London 2003; 256-281.
27. Zeng L., Fleury-Feith J., Monnet I. i wsp. Immunocytochemical characterization of cell lines from human malignant mesothelioma; charakterisation of human mesothelioma cell lines by Immunocytochemistry with a panel of monoclonal antibodies. Hum. Pathol. 1994; 25: 227-234.
28. Ordonez N.G. Value of cytokeratin 5/6 immunostanlng in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma. Am. J. Surg. Pathol. 1998; 22:1215-1221.
29. Chu P., Weiss L. Expression of cytokeratin 5/6 in epithelial neoplasms: an Immunohistochemical study of 509 cases. Mod. Pathol. 2002; 15: 6-10.
30. Wick M.R., Moran C.A., Ritter J.H., Mills S.E. Malignant and borderline mesothelial tumors of the pleura. W: Leslie K.O., Wick R.M. (red.). Practical pulmonary pathology. A diagnostic approach. Churchill Livingstone 2005; 733-744.